Treatment of Central Nervous System Involvement Associated with Primary Sjogren's Syndrome

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|14|13|1270-1273

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.13, 2008-05, pp. : 1270-1273

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Primary Sjogren's Syndrome and the Type I Interferon System

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 10, 2012-08 ,pp. : 2054-2062

Bentham Science Publishers

Access to resources Recommend Favorite

Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment

By  

Current Pharmaceutical Design, Vol. 14, Iss. 13, 2008-05 ,pp. : 1295-1301

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogren's Syndrome

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 9, Iss. 1, 2010-03 ,pp. : 10-19

Bentham Science Publishers

Access to resources Recommend Favorite

High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 8, Iss. 5, 2009-01 ,pp. : 380-386

Bentham Science Publishers

Access to resources Recommend Favorite

Mouse Models of Primary Sjogren’s Syndrome

By  

Current Pharmaceutical Design, Vol. 21, Iss. 18, 2015-06 ,pp. : 2350-2364

Bentham Science Publishers

Access to resources Recommend Favorite